| Candace Patrice Giles, DO | |
|
6829 N 72nd St Ste 4500, Omaha, NE 68122-1724 | |
| (402) 572-3790 | |
| Not Available |
| Full Name | Candace Patrice Giles |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 6829 N 72nd St Ste 4500, Omaha, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538435482 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | DO06129 (Idaho) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 1087 (Nebraska) | Primary |
| Entity Name | Memorial Community Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265408819 PECOS PAC ID: 0749190775 Enrollment ID: O20040202001065 |
News Archive
The onset of the flu season in the USA has been shown to be influenced by air travel. After flights were restricted following the 9/11 terrorist attacks in 2001, the flu season started about two weeks later than usual.
The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer.
Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001.
A preclinical study led by scientists at Sanford Burnham Prebys has established that AAV8-TNAP-D10-a gene therapy that replaces a key enzyme found in bone-may be a safe and effective single-dose treatment for hypophosphatasia (HPP).
› Verified 8 days ago
| Entity Name | Alegent Creighton Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548287907 PECOS PAC ID: 1951210418 Enrollment ID: O20040407001314 |
News Archive
The onset of the flu season in the USA has been shown to be influenced by air travel. After flights were restricted following the 9/11 terrorist attacks in 2001, the flu season started about two weeks later than usual.
The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer.
Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001.
A preclinical study led by scientists at Sanford Burnham Prebys has established that AAV8-TNAP-D10-a gene therapy that replaces a key enzyme found in bone-may be a safe and effective single-dose treatment for hypophosphatasia (HPP).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Candace Patrice Giles, DO 7261 Mercy Rd, Omaha, NE 68124-2311 Ph: () - | Candace Patrice Giles, DO 6829 N 72nd St Ste 4500, Omaha, NE 68122-1724 Ph: (402) 572-3790 |
News Archive
The onset of the flu season in the USA has been shown to be influenced by air travel. After flights were restricted following the 9/11 terrorist attacks in 2001, the flu season started about two weeks later than usual.
The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer.
Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001.
A preclinical study led by scientists at Sanford Burnham Prebys has established that AAV8-TNAP-D10-a gene therapy that replaces a key enzyme found in bone-may be a safe and effective single-dose treatment for hypophosphatasia (HPP).
› Verified 8 days ago
Dr. Elizabeth Stephens Constance, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 7308 S 142nd St, Omaha, NE 68138 Phone: 402-717-4200 | |
Jennifer Marie Burgart, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 7710 Mercy Rd Ste 202, Omaha, NE 68124 Phone: 402-280-4438 | |
Dr. Grace Binter, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 983255 Nebraska Medical Ctr, Omaha, NE 68198 Phone: 402-559-6160 | |
Dr. Stephanie Lynn Fisher Gustin, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 7308 S 142nd St, Omaha, NE 68138 Phone: 402-717-4200 Fax: 402-717-4231 | |
Dr. Alex Keith Laudenklos, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 601 N 30th St, Cu Department Of Obstetrics And Gynecology, Omaha, NE 68131 Phone: 402-717-0947 | |
Mr. Kent Harry Siemers, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 7205 W Center Rd, Suite 200, Omaha, NE 68124 Phone: 402-397-6600 Fax: 402-397-8318 | |
Dr. Brent Jonathan Tierney, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 8303 Dodge St, Suite 300, Omaha, NE 68114 Phone: 402-354-5250 Fax: 402-354-3437 |